Group 1: Key Research Projects - LZM012 targets IL-17A/F for moderate to severe psoriasis and ankylosing spondylitis, showing superior efficacy compared to control in Phase III trials, with PASI100 as the primary endpoint [2][5] - LZHN2408 for gout with hyperuricemia has received clinical approval, currently in Phase I trials, focusing on safety and efficacy [2] - H001, an anticoagulant for post-operative venous thromboembolism, has completed Phase II trials, showing comparable efficacy to enoxaparin with lower bleeding risk [3][7] - NS-041, a new generation KCNQ2/3 activator for epilepsy, has completed Phase I and is moving to Phase II, with no similar drugs on the market [3] - SG1001 for invasive fungal infections has completed Phase I trials, addressing drug resistance issues [3] - JP-1366, a P-CAB for gastrointestinal disorders, has completed Phase III trials and is preparing for market application [3] Group 2: Market Potential and Commercialization - The global market for psoriasis treatments is significant, with ustekinumab sales exceeding $6 billion in 2022, and UCB's bimekizumab projected to grow from $150 million in 2023 to over $600 million in 2024 [6][7] - LZM012 is expected to receive approval by mid-2027, aligning with the annual medical insurance negotiations [7] Group 3: Safety and Efficacy Data - LZM012's 52-week safety data shows a lower adverse reaction rate compared to ustekinumab, with no additional safety concerns identified [5] - H001's Phase I results indicate good safety profiles with no gastrointestinal bleeding, and preliminary data shows its anticoagulant effect is comparable to enoxaparin [7]